Ensho Health today announced a non-interventional secondary use of data study to assess the practical implications of adopting the H2FPEF and HFA-PEFF algorithms to screen for heart failure with preserved ejection fraction ("HFpEF") in routine clinical care (the "Study").
HFpEF is a phenotype of heart failure long suspected of being under-diagnosed. New clinical algorithms including H2FPEF and HFA-PEFF are intended to assist specialists in diagnosing HFpEF using information contained in electronic health records. Although these tools have the potential to improve diagnosis of HFpEF in clinical practice, the consequences of their adoption is not known. No epidemiological studies have examined the prevalence of undiagnosed HFpEF suggested by these algorithms or evaluated their accuracy at scale.
REVEAL will enroll de-identified electronic health records of approximately 37,500 consecutive patients managed by community cardiologists across Canada to determine the prevalence of undiagnosed HFpEF suggested by each algorithm, its accuracy in identifying HFpEF compared with data from right heart catheterizations and its potential role in clinical practice.
The Study is supported by Boehringer Ingelheim Canada.
About Ensho Health
Ensho Health is a health technology company whose mission is to empower healthcare providers to do more with data. It realizes its mission with solutions that improve patient outcomes and facilitate groundbreaking research. It operates clinical data labs that make machine learning and other clinically validated algorithms for early detection and individualized treatment of rare and complex diseases accessible to physicians and their patients, and provide information extraction services for secondary use of data studies with its Apollo aEDC system.